Market Overview

Marvell Holds Attractive Risk-Reward, BMO Says In Upgrade

Marvell Holds Attractive Risk-Reward, BMO Says In Upgrade
Related MRVL
Morgan Stanley's Key CES Takeaways For Semi Companies
Citi Adds Nvidia, Marvell Technology To Holiday Shopping List
Analog Devices report spurs semi optimism (Seeking Alpha)

Marvell Technology Group Ltd. (NASDAQ: MRVL) received another positive endorsement Tuesday from BMO Capital Markets after Friday's upgrade by Stifel. 

The Analyst

Analyst Ambrish Srivastava upgraded Marvell Tech from Market Perform to Outperform with a $24 price target, suggesting about 34-percent upside from current levels.

The Thesis

The risk-reward in Marvell Tech shares is attractive, with the possibility of $6 upside and $2 downside, Srivastava said in a Tuesday note. (See his track record here.) 

The estimates for the company are reasonable, "especially after Marvell cleared the deck on the Cavium estimates and management has a built a track record of executing," the analyst said. 

Marvell Tech completed its acquisition of fabless semiconductor company Cavium in July.

Marvell  has a strong track record of executing, Srivastava said.

The Price Action

Marvell Tech shares have lost about 15 percent year-to-date. The stock was up 2.8 percent at $18.63 at the time of publication Tuesday. 

Related Links:

KeyBanc Previews Q3 Semi Earnings, Downgrades Integrated Device Technology On Renesas Deal

KeyBanc Starts Coverage On 10 Semiconductor Stocks, Downgrades Cypress Semi

Latest Ratings for MRVL

Feb 2019MacquarieUpgradesNeutralOutperform
Feb 2019Craig-HallumDowngradesBuyHold
Dec 2018CitigroupUpgradesNeutralBuy

View More Analyst Ratings for MRVL
View the Latest Analyst Ratings

Posted-In: Ambrish Srivastava BMO Capital MarketsAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (MRVL)

View Comments and Join the Discussion!

Twilio Sells Off Following SendGrid Deal, But Analysts Remain Bullish

Mid-Day Market Update: Dow Rises Over 350 Points; Hanwha Q CELLS Shares Spike Higher